Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Porcine xenotransplantation

Executive Summary

FDA's Biological Response Modifiers Advisory Committee xenotransplantation subcommittee will meet June 3 and 4 to discuss scientific data concerning porcine endogenous retrovirus associated with porcine xenotransplantation. FDA will provide an update on xenotransplant policy development. A patient monitoring and screening update and proposals for solid organ xenotransplantation will also be considered. The committee discussed the best screening methods for porcine endogenous retrovirus in December 1997 ("The Pink Sheet" Dec. 22, 1997, T&G-6). The meeting will be held at the Holiday Inn, Bethesda, Md., beginning at 8:30 a.m. on June 3 and 8 a.m. on June 4
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel